文献速递神经免疫

奥瑞珠单抗治疗复发型多发性硬化五年:OPERA研究开放标签扩展结果

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
PubMed 文献 · Neurology · 2020-07-20

OPERA I/II研究开放标签扩展阶段评估奥瑞珠单抗(OCR)维持或由干扰素β-1a转换治疗对复发型多发性硬化临床与MRI结局及安全性的影响。进入扩展阶段患者中88.6%完成第5年,早期持续OCR治疗较转换治疗在24周确认残疾进展累积比例和全脑体积丢失方面更优,未出现新安全性信号。

要点

  • 早期持续OCR治疗5年较由IFN-β-1a转换者24周确认残疾进展累积比例更低(16.1% vs 21.3%,p=0.014)。
  • 持续OCR治疗者维持、转换者达到近乎完全且持续的新发脑MRI病灶活动抑制(第3-5年)。
  • 持续OCR治疗者全脑体积丢失较转换者更少(第5年-1.87% vs -2.15%,p<0.01),安全性与既往一致。

核心结论

  • 与由IFN-β-1a转换者相比,早期且持续OCR治疗至5年在疾病进展的临床和MRI指标上提供持续获益。

研究设计与样本

  • OPERA I/II研究开放标签扩展阶段,患者接受OCR 600 mg每24周静脉输注或由IFN-β-1a 44 μg每周三次转换为OCR,扩展期3年。
  • 进入扩展阶段患者中88.6%完成第5年。

主要发现

  • 第5年时早期OCR组24周确认残疾进展累积比例为16.1%,由IFN-β-1a转换组为21.3%(p=0.014)。
  • 持续OCR组维持、转换组达到第3-5年新发脑MRI病灶活动近乎完全且持续的抑制。
  • 第5年全脑体积变化持续OCR组为-1.87%,转换组为-2.15%(p<0.01)。
  • 不良事件与既往报告一致,长期治疗未出现新安全性信号。

临床怎么用

  • 对于复发型多发性硬化患者,早期启用并持续OCR治疗可能较延迟转换更有利于延缓残疾进展和脑萎缩。

局限性

  • 证据等级为Class III,因开放标签扩展入组后初始治疗随机化信息被披露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis. METHODS: After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed. RESULTS: Of patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year 5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from years 3-5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN-β-1a (-1.87% vs -2.15% at year 5; p < 0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment. CONCLUSION: Compared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that earlier and continuous treatment with OCR provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN-β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE. CLINICAL TRIAL IDENTIFIERS: NCT01247324/NCT01412333.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hauser SL, Kappos L, Arnold DL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020. PMID: 32690791. doi:10.1212/WNL.0000000000010376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。